- Home
- COGT vs AKBA Comparison
COGT vs AKBA Comparison
Compare COGT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- AKBA
- Stock Information
- Founded
- COGT 2014
- AKBA 2007
- Country
- COGT United States
- AKBA United States
- Employees
- COGT N/A
- AKBA N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- COGT Health Care
- AKBA Health Care
- Exchange
- COGT Nasdaq
- AKBA Nasdaq
- Market Cap
- COGT 806.1M
- AKBA 958.6M
- IPO Year
- COGT 2018
- AKBA 2014
- Fundamental
- Price
- COGT $7.41
- AKBA $3.63
- Analyst Decision
- COGT Buy
- AKBA Strong Buy
- Analyst Count
- COGT 6
- AKBA 5
- Target Price
- COGT $15.20
- AKBA $6.90
- AVG Volume (30 Days)
- COGT 2.4M
- AKBA 6.0M
- Earning Date
- COGT 08-05-2025
- AKBA 08-07-2025
- Dividend Yield
- COGT N/A
- AKBA N/A
- EPS Growth
- COGT N/A
- AKBA N/A
- EPS
- COGT N/A
- AKBA N/A
- Revenue
- COGT N/A
- AKBA $184,909,000.00
- Revenue This Year
- COGT N/A
- AKBA $26.88
- Revenue Next Year
- COGT N/A
- AKBA $44.34
- P/E Ratio
- COGT N/A
- AKBA N/A
- Revenue Growth
- COGT N/A
- AKBA N/A
- 52 Week Low
- COGT $3.72
- AKBA $0.91
- 52 Week High
- COGT $12.61
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- COGT 64.24
- AKBA 59.01
- Support Level
- COGT $7.07
- AKBA $3.60
- Resistance Level
- COGT $7.50
- AKBA $3.76
- Average True Range (ATR)
- COGT 0.43
- AKBA 0.18
- MACD
- COGT -0.06
- AKBA -0.05
- Stochastic Oscillator
- COGT 55.94
- AKBA 41.46
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.